[MO36] Mini-Oral Session 36　Palliative Care / Symptom Management 2

[MO36-4] Asian subgroup analysis in global POLAR program of calmangafodipir on top of mFOLFOX6 for the prevention of CIPN

^○Kei Muro¹, Kentaro Yamazaki², Keun-Wook Lee³, Kensei Yamaguchi⁴, Naotoshi Sugimoto⁵, Sang-Cheul Oh⁶, Taroh Satoh⁷, Sung Yong Oh⁸, Yoichiro Yoshida⁹, Dae Young Zang¹⁰, Ichiro Takemasa¹¹, Eiji Oki¹², Sang-Hee Cho¹³, Jaw-Yuan Wang¹⁴, Hiroshi Matsuoka¹⁵, Anders Persson¹⁶, Jacques Näsström¹⁶, Yusuke Sonehara¹⁷, Fumiko Nagahama¹⁷, Takeshi Kato¹⁸ (1.Aichi Cancer Center Hospital, 2.Shizuoka Cancer Center, 3.Seoul National University Bundang Hospital, Republic of Korea, 4.Cancer Institute Hospital of Japanese Foundation for Cancer Research, 5.Osaka International Cancer Institute, 6.Korea University Guro Hospital, Republic of Korea, 7.Osaka University Hospital, 8.Dong-A University Hospital, Republic of Korea, 9.Fukuoka University Hospital, 10.Hallym University Sacred Heart Hospital, Republic of Korea, 11.Sapporo Medical University Hospital, 12.Kyushu University Hospital, 13.Chonnam National University Hwasun Hospital, Republic of Korea, 14.Kaohsiung Medical University Chung-Ho Memorial Hospital, Taiwan, 15.Fujita Health University Hospital, 16.Egetis Therapeutics AB, Sweden, 17.Solasia Pharma K.K., Japan, 18.National Hospital Organization Osaka National Hospital,)